Citations

Clear

439 citation(s) found for "Stone, M".

Two birds with one stone: faster, fitter CAR T cells
Kenderian, Saad S.

Mayo Clinic

Blood | August 6, 2026 | Volume: 148 | Issue: 6 | Pages: 644-646

10.1182/blood.2026034331 | PMID 42560719 Get It

Bridging Conservative Management With Injectable Orthobiologic Therapies: Proceedings of the International Consensus Meetings on Cartilage Repair of the Ankle
Tham, Alexander, Rubin, Jared, Butler, James J., Gauthier, Paloma , Kennedy, John G. , Adams, Samuel B., Andrews, Carol L., Batista, Jorge , Baur, Onno L., Bayer, Stephen, Becher, Christoph, Berlet, Gregory C. , Boakye, Lorraine AT, Buda, R, Calder, James D. F., Dahmen, Jari , D’Hooghe, Pieter, DiGiovanni, Christopher W., Ehlers, M. , Ferkel, Richard D. , Ferkel, Eric, Ferrao, Paulo N. F., Giza, Eric , Gianakos, Arianna L., Glazebrook, Mark, Gomaa, Mohamed, Görtz, Simon, Haleem, Amgad M. , Hamid, Kamran S. , Hangody, László, Haverkamp, Daniel, Hertel, Jay, Hintermann, Beat, Hogan, MaCalus V., Hunt, Kenneth J., Hurley, Eoghan T., Karlsson, Jon, Kearns, Stephen R. , Kerkhoffs, Gino M. M. J., Kim, Hak Jun , Kong, Siu Wah, Krebsbach, Sebastian, Labib, Sameh A. , Lambers, Kaj T. A. , Lee, Jin Woo, Lee, Keun Bae, Ling, Jeffrey S., Longo, Umile Giuseppe, Marangon, Alberto, McCollum, G, McCullough, Kirk, Mittwede, Peter N. , Murawski, Christopher D. , Nicolescu, Raluca, Niemeyer, Philipp, Nunley, James A., O'Malley, Martin, Ortiz, Cristian, Osei-Hwedieh, David O. , Paul, Jochen , Pearce, Christopher J., Pereira, Hélder , Phadke, Rohan , Prado, Marcelo P. , Raikin, Steven M., Reilingh, Mikel L., Robert, Guillaume , Lc, Schon, Simpson, Helene, Smyth, Niall A. , Sofka, Carolyn M., Spennacchio, Pietro, Stone, James W., Takao, M, Tanaka, Yasuhito, Thermann, Hajo, Thordarson, David B. , Rs, Tuan, Valderrabano, Victor, Bergen, Christian J. A. van, Dijk, Pim A. D van, Dijk, Niek van, Vannini, Francesca, Vaseenon, Tanawat , Volesky, Monika , Walls, Raymond C., Walther, Markus, Wiewiorski, Martin, Xu, Xiangyang, Yasui, Youichi , Yinghui, Hua, Yoshimura, Ichiro, Younger, Alastair , Zdanowicz, Urszala, Zhang, Zijun, Adams, Samuel B. , Clanton, Thomas O , Dahmen, Jari , Ehlers, Mallory , Hannon, Charles P , Labib, Sameh A , Popchak, Adam , Robert, Guillaume , Smyth, Niall A , Tham, Alexander , Rubin, J Peter , Butler, James J., Angthong, Chayanin , Becher, Christoph, Boakye, Lorraine A. T. , Buda, Roberto , Calder, James D. F. , Canata, Gian Luigi , Carreira, Dominic S. , Dahmen, Jari , d’Hooghe, Pieter P. R. N. , DiGiovanni, Christopher William , Dombrowski, Malcolm E. , Ferkel, Eric I. , Ferrao, Paulo N. F. , Gianakos, Arianna L. , Glazebrook, Mark Anthony , Gomaa, Mohamed, Hannon, Charles P. , Haverkamp, Daniël , Hintermann, Beat , Hogan, MaCalus Vinson , Hunt, Kenneth John , Hurley, Eoghan T. , Karlsson, Jon, Kerkhoffs, Gino M. M. J. , Krebsbach, Sebastian , Lee, Jin Woo , Longo, Umile Giuseppe , Mitchell, Adam W. , Nehrer, Stefan , Niemeyer, Philipp , Nunley, James A. , O’Malley, Martin , Pearce, Christopher Jon , Pereira, Hélder , Raikin, Steven M. , Rothrauff, Benjamin B. , Schon, Lew Charles , Spennacchio, Pietro , Sullivan, Martin, Tanaka, Yasuhito , Valderrábano, Víctor , Dijk, Pim A. D. van , Vannini, Francesca , Walther, Markus , Wiewiorski, Martin J., Xu, Xiangyang , Yoshimura, Ichiro , Zhang, Zijun

Mayo Clinic

Foot & Ankle Specialist | July 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/19386400261456925 | PMID 42495946 Get It

Background The management of osteochondral lesions of the talus (OLT) is challenging, with 2 main options being conservative and surgical management. Orthobiologic therapies come to bridge the gap between these 2 options; however, inconsistencies in indication, composition, and heterogeneous evidence limit clinical decision-making. To address these challenges, 3 International Congress Meetings on Cartilage Repair of the Ankle were convened in Pittsburgh, USA (2017), Dublin, Ireland (2019), and New York, USA (2025) to establish agreement on the role of conservative management and injectable orthobiologic strategies in the treatment of OLT. Methods Seventy-five multidisciplinary experts from over 25 countries and 1 territory participated in a structured Delphi-based consensus process. Blinded surveys, structured questionnaires, and in-person discussions were used to develop and refine statements, supported by literature review and graded evidence (A1–E). Consensus strength was defined as consensus (51%-74%), strong consensus (75%-99%), or unanimous (100%) Results In total, 29 consensus statements were achieved across the 3 meetings. Strong agreement was reached regarding indications and expected outcomes of conservative management, including the role of immobilization and appropriate timing for surgical intervention. Orthobiologic injections, including platelet-rich plasma, concentrated bone marrow aspirate, and hyaluronic acid, were considered appropriate in select patients with persistent symptoms, although no superiority was demonstrated among formulations, preparation methods, or injection strategies. When used as adjuncts to surgical procedures, orthobiologics may improve radiological outcomes, with limited evidence for improvement in clinical outcomes. Technical considerations, including preferred harvest sites and a lack of standardized preparation protocols, were identified, along with key principles for patient counseling Conclusion These international consensus statements establish a standardized framework for the conservative management and use of injectable orthobiologic therapies in OLT. By clarifying indications, technical considerations, and current limitations, this work aims to improve consistency in clinical practice, guide treatment decision-making, and inform future research.
Safety and preliminary efficacy of allogeneic bone marrow-derived mesenchymal stromal cells (BMSC) for painful lumbar facet arthropathy: study protocol for a randomised, double-blinded, placebo-controlled, crossover phase II clinical trial
Yan, Dan , Durand, Nisha , Wang, Z, Osborne, Michael D. , Gupta, Sahil, Miller, David A, Witter, Drew M., Eldrige, Jason S. , Quiñones-Hinojosa, Alfredo, Zubair, Abba C, Qu, Wenchun , Durand, Nisha C, Stone, Jeffrey A, Stone, Jeffrey A, Quiñones‐Hinojosa, Alfredo , Zubair, Abba C.

Mayo Clinic

BMJ Open | July 20, 2026 | Volume: 16 | Issue: 7 | Pages: e113509

10.1136/bmjopen-2025-113509 | PMID 42476734 Get It

Background Lumbar facet arthropathy (LFA) is a degenerative, arthritic joint disorder and a common specific cause of axial low back pain and functional impairment. Currently, no disease-modifying therapies are available for symptomatic LFA. Mesenchymal stem/stromal cell (MSC)-based therapy represents an emerging regenerative treatment modality with the promise to target the underlying pathophysiology of LFA. Despite encouraging clinical evidence supporting the safety and efficacy of MSC therapy in other osteoarthritis, its therapeutic utility in LFA remains largely unexplored. We recently completed a prospective, single-arm, open-label phase I clinical trial that demonstrated a favourable safety profile and preliminary clinical benefit following intra-articular administration of bone marrow-derived MSCs (BMSCs) in patients with symptomatic LFA. Building on these findings, we present the protocol for CellKine II , a prospective, randomised, double-blind, placebo-controlled, cross-over phase II clinical trial to evaluate the safety and preliminary efficacy of intra-articular delivery of allogeneic, culture-expanded BMSCs in patients with painful LFA. Methods and analysis This study is a single-centre, randomised, double-blind, placebo-controlled, cross-over phase II trial with a target accrual of 40 patients. Eligible patients will be randomly assigned in a 1:1 ratio to receive a single intra-articular injection of either Arm A: BMSC or Arm B: Placebo (dimethyl sulfoxide). At the 6-month follow-up, all patients will be unblinded. Patients initially randomised to Arm A will continue follow-up for up to 12 months. Patients initially randomised to Arm B may cross over to receive the BMSC treatment, followed by an additional 12 months of post-BMSC treatment follow-up, or they may continue observation for another 6 months without BMSC treatment. Overall, each patient will be followed up to 12 months after BMSC treatment. The primary endpoints are back pain, functional outcomes and adverse events at 6 months post-randomisation. Ethics and dissemination This study will be conducted in compliance with U.S. federal regulations and Mayo Clinic institutional research policies and procedures. The protocol has been approved by the Mayo Clinic Institutional Review Board (IRB) and the Data Safety Monitoring Board (IRB No. 21-013278). The results of this trial will be disseminated through publication in peer-reviewed journals and on ClinicalTrials.gov. Trial registration number NCT06001853 .
PRANA: A Deep Learning Method for Adapting Polygenic Risk Scores to Diverse Ethnic Groups
Levi, Hagai, Wang, Qin, Bolla, Manjeet K. , Dennis, Joe, Andrulis, Irene L., Antonenkova, Natalia, Au, Chun Hang, Freeman, Laura E. Beane, Bermisheva, Marina, Bodelon, Clara, Bojesen, Stig E., Brenner, Hermann, Brock, Ian W., Brüning, Thomas, Byers, Helen, Camp, Nicola J., Castelao, Jose E., Choi, Ji-Yeob, Chung, Wendy K., Collaborators, NBCS, Colonna, Sarah, Couch, Fergus J., Daly, Mary B., Devilee, Peter, Dörk, Thilo, Eliassen, A. Heather, Eriksson, Mikael, Evans, D. Gareth, Fasching, Peter A., Faw, Kierstin, García-Closas, Montserrat, Haiman, Christopher A., Hamann, Ute, Hartman, Mikael, Hooning, Maartje J., Hoppe, Reiner , Howell, Sacha J., Investigators, ABCTB, Investigators, SGBCC, Ito, Hidemi, Iwasaki, Motoki, Jakubowska, Anna, Jernström, Helena, Joseph, Vijai, Kaaks, Rudolf, Kang, Daehee, Khusnutdinova, Elza K., Kiprijanovska, Sanja , Koutros, Stella, Kristensen, Vessela N., Kurian, Allison W., Kwong, Ava, Lambrechts, Diether, Larson, Nicole L. , Marchand, Loic Le, Li, Shuai, Li, Jingmei, Lophatananon, Artitaya, Mannermaa, Arto, Matsuo, Keitaro, Maxwell, Whitney, Muir, Kenneth, Nevelsteen, Ines, Obi, Nadia, O’Brien, Katie M., Ofit, Kenneth, Ottewell, Penelope D., Patel, Alpa V., Plaseska-Karanfilska, Dijana, Prajzendanc, Karolina , Ramachandran, Dhanya, Rashid, Muhammad U., Saloustros, Emmanouil, Sandler, Dale P., Schöttker, Ben, Simard, Jacques, Southey, Melissa C., Stone, Jennifer, Teras, Lauren R., Truong, Thérèse, Weinberg, Clarice R., Yamaji, Taiki , Zheng, Wei, Easton, Douglas F., Elkon, Ran , Lambrechts, Diether , Lambrechts, Diether , Kurian, Allison W. , Li, Shuai , Lambrechts, Diether , Lambrechts, Diether , Kurian, Allison W , Li, Shuai , Levi, Hagai , Au, Chun , Augustinsson, Annelie , Freeman, Laura E. Beane , Behrens, Sabine , Bermisheva, Marina , Bodelón, Clara , Bogdanova, Natalia , Brenner, Hermann , Brock, Ian W., Brüning, Thomas , Byers, Helen, Camp, Nicola J. , Castelao, Jose E. , Choi, Ji-Yeob , Chung, Wendy K. , Colonna, Sarah V. , Couch, Fergus J. , Czene, Kamila , Daly, Mary B., Devilee, Peter , Dörk, Thilo, Evans, D. Gareth , Fasching, Peter A., Faw, Kierstin, Gago-Domínguez, Manuela , García‐Closas, Montserrat , Haiman, Christopher A. , Hartman, Mikael , Ho, Vikki , Ho, Peh Joo , Hooning, Maartje J. , Investigators, S On Behalf Of The Chlovis Study, Iwasaki, Motoki , Jakubowska, Anna, Jernström, Helena , Joseph, Vijai, Kaaks, Rudolf , Хуснутдинова, Э. К. , Koutros, Stella , Kristensen, Vessela N., Kwong, Ava , Marchand, Loı̈c Le , Li, Jingmei, Lophatananon, Artitaya , Mannermaa, Arto , Nevelsteen, Ines , Obi, Nadia , O’Brien, Katie M. , Ottewell, Penelope Dawn , Peterlongo, Paolo , Plaseska‐Karanfilska, Dijana , Radice, Paolo , Ramachandran, Dhanya , Romero, Atocha , Saloustros, Emmanouil , Sandler, Dale P. , Schöttker, Ben , Simard, Jacques , Southey, Melissa C. , Sugier, Pierre‐Emmanuel , Taylor, Jack A. , Teras, Lauren R. , Truong, Thérèse , Weinberg, Clarice R. , Yadav, Siddhartha , Dunning, Alison M. , Mavaddat, Nasim , Easton, Douglas F. , Michailidou, Kyriaki , Shamir, Ron

Mayo Clinic

No container title available | July 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.12.26357860 | PMID 42523604 Get It

Abstract Polygenic risk scores (PRSs), which quantify inherited susceptibility to complex traits and diseases, have emerged as valuable tools for risk stratification and precision medicine. Despite their promise, PRS developed on European cohorts often demonstrate substantially reduced predictive accuracy in non-European populations, due to differences in genetic architecture. The disproportionate representation of European ancestry cohorts in genome-wide association studies (GWAS) leads to inequitable deployment of PRS technologies across diverse populations. Here, we introduce PRANA (Polygenic Risk Adaptation via Neural-network Architecture), a deep learning framework that adapts an existing PRS developed on one population to other ancestries. Unlike methods that require large-scale GWAS in the target population, PRANA leverages pre-trained PRS models derived from European cohorts and adapts them using modestly sized cohorts from the target population. We evaluated PRANA on seven complex traits in South Asian, East Asian and Ashkenazi Jewish populations, as well as in selected smaller East Asian subpopulations where the scarcity of training data poses a particular challenge. PRANA mostly improved predictive performance of the baseline PRS models by 5%-20% in terms of effect size (β) and Nagelkerke’s R², and, in most cases, outperformed existing cross-ancestry multi-PRS approaches. These results highlight PRANA as a scalable and practical strategy to reduce disparities in genomic risk prediction and advance the equitable application of PRS in diverse populations.
NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026
Patel, Anand , Patel, Anand , Pollyea, Daniel Aaron , Altman, Jessica K. , Assi, Rita, Bachiashvili, Kimo, Bhatt, Vijaya Raj , Fathi, Amir T. , Fedorov, Kateryna, Foran, James M. , Gojo, Ivana , Goldberg, Aaron, Hall, Aric C. , Jonas, Brian A., Levine, Matthew R., Mangan, James, Mannis, Gabriel N. , Marcucci, Guido , Mims, Alice S , Moriarty, Kelsey, Ali, Moaath Mustafa, Neff, Jadee , Nejati, Reza , Olin, Rebecca L. , Patel, Anand, Percival, Mary‐Elizabeth M. , Perl, Alexander E. , Pettit, Kristen, Rao, Dinesh S. , Ravandi‐Kashani, Farhad, Schwabkey, Zaker, Shallis, Rory, Stahl, Maximilian, Stone, Richard M. , Thota, Swapna, Uy, Geoffrey L., Walker, Alison, Wang, Eunice, Awotiwon, Ajibola, Roth, Sydney L., Stehman, Katie

Mayo Clinic

Journal of the National Comprehensive Cancer Network | June 15, 2026 | Volume: 24 | Issue: 6 | Pages: 222-229

10.6004/jnccn.2026.0028 | PMID 42297017 Get It

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. It is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths from leukemias in the United States. 1 The NCCN Guidelines Panel for AML convenes annually to update recommendations for the diagnosis and treatment of AML in adults. These recommendations are based on a review of recently published clinical trials that have led to significant improvements in treatment or have yielded new information regarding biologic factors that may have prognostic importance. These NCCN Guidelines Insights summarize the panel’s most recent recommendations regarding the monitoring and management of measurable (minimal) residual disease.
Decompression with or without Duraplasty for Chiari I and Syringomyelia
Limbrick, David D. , Shannon, Chevis N., Bayman, Emine O., Meehan, Thanda, Kallem, Marisa, Ackerman, Laurie L. , Adelson, P. David , Albert, Gregory, Aldana, Philipp R. , Alden, Tord D. , Anderson, Richard C. E. , Baird, Lissa C., Bauer, David, Bethel-Anderson, Tammy, Bierbrauer, Karin, Brockmeyer, Douglas L. , Chern, Joshua J. , Couture, Daniel, Daniels, David J., Dauser, Robert C., Durham, Susan, Ellenbogen, Richard G., Eskandari, Ramin, Gannon, Stephen R., Grant, Gerald A., Greene, Stephanie, Gross, Naina L. , Guillaume, Daniel J. (Daniel James), Hankinson, T., Heuer, Gregory, Iantosca, Mark, Iskandar, Bermans J. , Jackson, Eric M., Keating, Robert F., Kelly, Michael P., Kennedy, Elaine, Krieger, Mark D., Kulkarni, Abhaya V., Labuda, Rick, Leonard, Jeffrey R., Maher, Cormac O. , Mangano, Francesco T. , McComb, J. Gordon, McEvoy, Sean D., Niazi, Toba N., Oakes, Jerry, Olavarria, Greg, O’Neill, Brent R., Poppe, Dorothy, Ragheb, John, Reynolds, Lisa, Selden, Nathan R., Shah, Manish N., Smyth, Matthew D., Spears, Sandy, Stone, Scellig , Strahle, Jennifer M., Tamber, M, Tramelli, Gina, Tuite, Gerald F. , Vance, Haley, Wait, Scott D. , Wellons, John C. , Whitehead, WE, Yahanda, Alexander T., Yan, Yan, Dacey, Ralph G. , Park, Tae Sung, Torner, James C., Kelly, Michael P. , Torner, James C. , Dlouhy, Brian J , Iskandar, Bermans J , Yahanda, Alexander T , Kelly, Michael P , Limbrick, David D. , Bayman, Emine O. , Ahmed, Raheel , Albert, Gregory W. , Bierbrauer, Karin S. , Daniels, David J. , Ellenbogen, Richard G., Graupman, Patrick C. , Greenberg, Jacob K , Greenfield, Jeffrey P. , Guillaume, Daniel, Iantosca, Mark, Jackson, Eric M., Jallo, George I. , Johnston, James M. , Keating, Robert F., Kennedy, Elaine, Kulkarni, Abhaya V. , McComb, J. Gordon , McKinstry, Robert C. , Menezes, Arnold H. , Poppe, Dorothy , Ragheb, John , Reeves, Samuel, Reynolds, Lisa, Selden, Nathan R. W. , Shah, Manish N. , Shimony, Joshua S. , Strahle, Jennifer M. , Tamber, Mandeep S. , Tyler‐Kabara, Elizabeth C. , Vance, E. Haley, Yahanda, Alexander T. , Park, Tae Sung

Mayo Clinic

New England Journal of Medicine | May 27, 2026 | Volume: 394 | Issue: 20 | Pages: 2015-2025

10.1056/nejmoa2402821 | PMID 42202320 Get It

Inflammation, mechanical allodynia and an exaggerated exercise pressor reflex during disease progression in UCD‐type 2 diabetes mellitus rats
McCuller, Richard K., Huo, Yu, Gajula, Amshula N., Ybarbo, Kai, Stone, Audrey J. , Stone, Audrey J , Harrison, Michelle , Huo, Yu, Ybarbo, Kai M., Ryzin, Mark J. Van, Stanhope, Kimber L. , Havel, Peter Joseph

Mayo Clinic

Experimental Physiology | May 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1113/ep093516 | PMID 42086336 Get It

Abstract Chronic low‐grade inflammation characterizes type 2 diabetes mellitus (T2DM) and underlies the development of peripheral neuropathy, symptoms of which include mechanical allodynia and an exaggerated exercise pressor reflex. The purpose of this study was to determine whether mechanical allodynia and/or specific concentrations of inflammatory mediators coincide with the presence of an exaggerated exercise pressor reflex. Haemoglobin A1c was assessed to detect diabetes onset (threshold ≥5.6%) in male University of California Davis (UCD)‐T2DM rats ( n = 18). Age‐matched, healthy Sprague–Dawley rats ( n = 18) served as controls. Monthly measurements assessed mechanical allodynia (via paw withdrawal threshold), insulin and inflammatory mediators (via ELISA and multiplex kits). Paw withdrawal threshold was not different between groups prior to diabetes onset. However, by 8 weeks post‐onset, T2DM rats demonstrated a significant decrease in pain threshold compared to that before diabetes onset, which persisted for 8 weeks. This is the same period in diabetes progression as when the exercise pressor reflex is exaggerated. Prior to diabetes onset, UCD‑T2DM rats had significantly higher circulating levels of IL‑6 and IL‑1β, and these elevations persisted throughout disease progression, with only CRP showing a significant increase at 8 weeks post‑onset. These findings offer a useful foundation for further exploration into the assessments of mechanical allodynia and inflammation to determine when those with T2DM are at an increased risk for experiencing adverse cardiovascular events.
Expert Recommendations for Rapid Response to Positive Newborn Screen for Infantile Krabbe Disease
Thompson-Stone, Robert , White, Amy , Rubin, Jennifer , Rajan, Deepa , Matern, Dietrich , Kurtzberg, Joanne , Orsini, Joseph J. , Shenoy, Shalini , Mallack, Eric J. , Ream, Margie , White, Amy L , Rubin, Jennifer P , Rajan, Deepa Soundara , Ream, Margie A , Kurtzberg, Joanne , Orsini, Joseph J

Mayo Clinic

Neurology Genetics | April 22, 2026 | Volume: 12 | Issue: 3 | Pages: No page available

10.1212/nxg.0000000000200383 | PMID 42040243 Get It

Investigating the impact of problematic evidence on clinical practice guidelines and associated patient outcomes (VITALITY Study II): protocol
Xu, Chang, Kanamori, Luis Furuya, Cao, Hong, Wang, Xinyi, Li, Sheyu, Wen, Tianmeng, Fan, Shiqi , Gu, Zhichun , Lin, Lifeng, Yisha, Zuhaer , Cristea, Ioana Alina, Du, Liang, Clark, Juli, Zeng, Linan, Fan, Zhaohu , Golder, Su, Murad, M Hassan, Lin, Houwen, Mol, Ben W, Vohra, Sunita, Doi, Suhail A, Li, Sheyu , Clark, Justin , Xu, Chang , Li, Sheyu , Lin, Lifeng , Clark, Justin , Golder, Su , Murad, M Hassan , Mol, Ben W , Furuya‐Kanamori, Luis , Loke, Yoon Kong , Wen, Tianmeng , Stone, Jennifer , Cristea, Ioana A. , Du, L. C. , Qin, Zongshi , Song, Yang , Chu, Haitao , Vohra, Sunita , Doi, Suhail A

Mayo Clinic

BMJ Open | March 31, 2026 | Volume: 16 | Issue: 3 | Pages: e115303

10.1136/bmjopen-2025-115303 | PMID 41916628 Get It

Introduction Increasing publication of fraudulent clinical trials poses a serious threat to evidence-based medicine. In the VITALITY Study I, we demonstrated that contamination by retracted trials significantly distorts evidence synthesis. The upcoming VITALITY Study II will take a step further and investigate how such problematic evidence undermines the credibility of guideline recommendations. Methods and analyses The VITALITY Study II will adopt a retrospective cohort design and will be structured as three work packages (WPs). To start with, a cohort of clinical practice guidelines (CPGs) that were contaminated by retracted trials and/or meta-analyses that included retracted trials will be established based on forward citation searching (WP1). Then, recommendations from these CPGs that used evidence from retracted trials and/or meta-analyses that synthesised these retracted trials will be re-evaluated after removing such problematic evidence, in terms of both the direction and strength of effect sizes (WP2). Finally, the subsequent impact on patient outcomes attributable to distorted recommendations will be estimated on a hypothetical population, measured by the number of expected benefit loss and the number of expected harm increment per 100 000 patients (WP3). Ethics and dissemination Formal ethical approval is not necessary for this study as it does not involve human or animal participants, nor does it involve the collection of primary data. We will disseminate the findings through publication in peer-reviewed journals and, whenever possible, presentations at academic conferences.